Cryptococcemia in a patient with COVID-19: A case report
- PMID: 33598258
- PMCID: PMC7869327
- DOI: 10.1002/ccr3.3668
Cryptococcemia in a patient with COVID-19: A case report
Abstract
The authors urge clinicians to balance the use of Immunosuppressant drugs and tocilizumab for COVID-19 patients to avoid the development of infections like Cryptococcemia, leading to death within 30 days.
Keywords: COVID‐19; Cryptococcus neoformans; corticosteroids; cryptococcemia; tocilizumab.
© 2020 The Authors. Clinical Case Reports published by John Wiley & Sons Ltd.
Conflict of interest statement
The authors declare that they have no competing interests.
References
-
- Cox G, Perfect J. Cryptococcus neoformans var. neoformans and gattii and Trichosporon species In Topley and Wilson's Microbiology and Microbial Infections, 9th edn. London: Arnold Press; 1997:461‐484.
-
- Lee SC, Dickson DW, Casadevall A. Pathology of cryptococcal meningoencephalitis: analysis of 27 patients with pathogenetic implications. Hum Pathol. 1996;27(8):839‐847. - PubMed
-
- Baker RD. The primary pulmonary lymph node complex of cryptococcosis. Am J Clin Pathol. 1976;65(1):83‐92. - PubMed
Publication types
LinkOut - more resources
Full Text Sources